Mostrar el registro sencillo del ítem

Impacto del cultivo de células madre y sus aplicaciones

dc.contributor.authorSanchez Mora, Ruth Melida
dc.contributor.authorGómez Jiménez, Martha
dc.contributor.authorGualteros Bustos, Andrea Viviana
dc.date.accessioned2022-05-23T20:35:18Z
dc.date.available2022-05-23T20:35:18Z
dc.date.issued2021
dc.identifier.isbn9789585198029spa
dc.identifier.urihttps://repositorio.universidadmayor.edu.co/handle/unicolmayor/5562
dc.descriptionIncluye índice de abreviaturas. -- Incluye referencias bibliográficasspa
dc.description.abstractEl impacto de los cultivos de células madres (CMs) se ha reflejado en múltiples aplicaciones a través del tiempo, desde el análisis, la caracterización de vías, moléculas y mecanismos de señalización, implicados en patologías humanas, hasta el descubrimiento de nuevos fármacos y blancos terapéuticos utilizados como solución para estas. Los avances en tecnologías de punta han permitido el desarrollo de nuevos equipos, materias primas y nuevas técnicas moleculares que actualmente facilitan la aplicación de cultivos de CMs en terapias celulares para el tratamiento de enfermedades crónicas y la regeneración de tejidos. En las nuevas técnicas y metodologías de cultivos celulares se busca lograr reproducibilidad, exactitud y precisión, con el fin de diseñar cultivos que imiten las condiciones en que las CMs se encuentran in vivo, que permita lograr una mayor certeza e impacto en su aplicabilidad, así como en el diseño de materiales ambientalmente sostenibles y de fácil manipulación. El avance en los cultivos de CMs se ve reflejado en la creación de bancos públicos de aislamiento, identificación y crio preservación de CMs de sangre de cordón umbilical. Colombia se constituye en el cuarto país después de México, Brasil y Argentina en el que se proyecta actualmente el tratamiento de enfermedades huérfanas, crónicas y metabólicas en poblaciones vulnerables (trasplantes alogénicos) o en los mismos donantes de CMs (trasplantes autólogos). El programa Cordial, desarrollado por el Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud (IDCBIS), desde el año 2011fomenta la donación de sangre de cordón umbilical por parte de maternas en diferentes regiones de Colombia, con el propósito de obtener la mayor diversidad genética y así disminuir los costos de importación de CMs, lo cual mejore la disponibilidad y la oportunidad en los tratamientos, además de implementar una base de datos que facilita la búsqueda de CMs teniendo como criterio principal la compatibilidad. De esta manera, los cultivos de CMs se convierten en una herramienta útil para el avance en diferentes áreas del conocimiento.spa
dc.description.tableofcontentsLista de figuras Lista de tablas Glosario Índice de abreviaturas Prólogo 1. Cultivo de células madre: aislamiento e identificación 1.1 Clasificación de las células madre 1.2. Aspectos preliminares del cultivo de células madre 1.2.1 Microambiente, microentorno o nicho 1.2.2 Matriz extracelular 1.3 Aislamiento de células madre para cultivo 1.3.1 Método de gradiente de densidad de Ficoll 1.3.2 Método de dispositivo de filtro de médula ósea 1.3.3 Método de digestión (colagenasa) 1.3.4 Método de filtración por membrana 1.4 Identificación de células madre 1.4.1 CD90 (cluster of differentiation 90) 1.4.2 CD73 o 5’-nucleotidasa 1.4.3 CD105 o endoglina 1.4.4 STRO-1 1.4.5 CD106 (cluster of differentiation 106) 2. Autorrenovación y mantenimiento de células madre 2.1 Autorrenovación de las células madre 2.2 Mantenimiento de cultivos de células madre 2.2.1 Cultivo de mantenimiento de células madre mesenquimales provenientes de tejido adiposo 2.2.2 Cultivo de mantenimiento de células madre mesenquimales provenientes de explantes dentales 2.2.3 Cultivo de mantenimiento de células madre mesenquimales provenientes de cordón umbilical 2.3 Diferenciación dirigida de células madre 2.3.1 Condrogénesis 2.3.2 Osteogénesis 2.3.3 Adipogénesis 2.4 Métodos de criopreservación de células madre 2.4.1 Procedimiento convencional de congelación lenta 2.4.2 Procedimiento de enfriamiento ultrarrápido 2.5. Control de calidad y buenas prácticas de fabricación 3. Sistemas de cultivo de células madre 3.1 Cultivos en monocapa 3.2 Cultivos 2D 3.3 Cultivos 3D 3.4 Organoides 3.5 Cultivos en biorreactor 4. Aplicaciones de los cultivos de células madre 4.1 Las células madre pluripotentes inducidas como modelo para enfermedades 4.2 Aplicaciones de los modelos organoides 4.3 Las células madre mesenquimales como modelo para enfermedades 4.3.1 Las células madre mesenquimales en enfermedades autoinmunes 4.3.2 Células madre mesenquimales en tratamiento de cáncer 4.3.3 Células madre mesenquimales en enfermedades neurodegenerativas Conclusión Referenciasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.titleImpacto del cultivo de células madre y sus aplicacionesspa
dc.typeLibrospa
dcterms.extent96 páginas.
dc.coverage.countryColombia
dc.description.edition1a. ed.
dc.publisher.editorUniversidad Colegio Mayor de Cundinamarca
dc.publisher.placeBogotá, Colombia, 2021spa
dc.relation.references1. Saito MT, Silverio KG, Casati MZ, Sallum EA, Nociti FH, Jr. Tooth-derived stem cells: Update and perspectives. World journal of stem cells. 2015;7(2):399-407.spa
dc.relation.references2. Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis research & therapy. 2007;9(1):204.spa
dc.relation.references3. Bao M, Xie J, Huck WTS. Recent Advances in Engineering the Stem Cell Microniche in 3D. Advanced science. 2018;5(8):1800448.spa
dc.relation.references4. Ouryazdanpanah N, Dabiri S, Derakhshani A, Vahidi R, Farsinejad A. Peripheral Blood-Derived Mesenchymal Stem Cells: Growth Factor-Free Isolation, Molecular Characterization and Differentiation. Iranian journal of pathology. 2018;13(4):461-6.spa
dc.relation.references5. Rye PD, Hoifodt HK, Overli GE, Fodstad O. Immunobead filtration: a novel approach for the isolation and propagation of tumor cells. The American journal of pathology. 1997;150(1):99-106.spa
dc.relation.references6. Hibino N, Nalbandian A, Devine L, Martinez RS, McGillicuddy E, Yi T, et al. Comparison of human bone marrow mononuclear cell isolation methods for creating tissue-engineered vascular grafts: novel filter system versus traditional density centrifugation method. Tissue engineering Part C, Methods. 2011;17(10):993-8.spa
dc.relation.references7. Pillai SG, Zhu P, Siddappa CM, Adams DL, Li S, Makarova OV, et al. Enrichment and Molecular Analysis of Breast Cancer Disseminated Tumor Cells from Bone Marrow Using Microfiltration. PloS one. 2017;12(1):e0170761.spa
dc.relation.references8.Raposio E, Simonacci F, Perrotta RE. Adipose-derived stem cells: Comparison between two methods of isolation for clinical applications. Annals of medicine and surgery. 2017;20:87-91.spa
dc.relation.references9. Ishii K, Suzuki N, Mabuchi Y, Sekiya I, Akazawa C. Technical advantage of recombinant collagenase for isolation of muscle stem cells. Regenerative therapy. 2017;7:1-7.spa
dc.relation.references10. De Francesco F, Mannucci S, Conti G, Dai Pre E, Sbarbati A, Riccio M. A Non-Enzymatic Method to Obtain a Fat Tissue Derivative Highly Enriched in Adipose Stem Cells (ASCs) from Human Lipoaspirates: Preliminary Results. International journal of molecular sciences. 2018;19(7).spa
dc.relation.references11. Qu C, Yan M, Yang S, Wang L, Yin Q, Liu Y, et al. Haploid embryonic stem cells can be enriched and maintained by simple filtration. The Journal of biological chemistry. 2018;293(14):5230-5.spa
dc.relation.references12. Lin HR, Heish CW, Liu CH, Muduli S, Li HF, Higuchi A, et al. Purification and differentiation of human adipose-derived stem cells by membrane filtration and membrane migration methods. Scientific reports. 2017;7:40069.spa
dc.relation.references13. Schlinker AC, Radwanski K, Wegener C, Min K, Miller WM. Separation of in-vitro-derived megakaryocytes and platelets using spinning-membrane filtration. Biotechnology and bioengineering. 2015;112(4):788-800.spa
dc.relation.references14. Klymiuk MC, Balz N, Elashry MI, Heimann M, Wenisch S, Arnhold S. Exosomes isolation and identification from equine mesenchymal stem cells. BMC veterinary research. 2019;15(1):42.spa
dc.relation.references15. Khan FA, Almohazey D, Alomari M, Almofty SA. Isolation, Culture, and Functional Characterization of Human Embryonic Stem Cells: Current Trends and Challenges. Stem cells international. 2018;2018:1429351.spa
dc.relation.references16. Lin CS, Xin ZC, Dai J, Lue TF. Commonly used mesenchymal stem cell markers and tracking labels: Limitations and challenges. Histology and histopathology. 2013;28(9):1109-16.spa
dc.relation.references17. Morris RJ. Thy-1, a Pathfinder Protein for the Post-genomic Era. Frontiers in cell and developmental biology. 2018;6:173.spa
dc.relation.references18. Bradley JE, Ramirez G, Hagood JS. Roles and regulation of Thy-1, a context-dependent modulator of cell phenotype. BioFactors. 2009;35(3):258-65.spa
dc.relation.references19. Barry F, Boynton R, Murphy M, Haynesworth S, Zaia J. The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochemical and biophysical research communications. 2001;289(2):519-24.spa
dc.relation.references20. Katsuta E, Tanaka S, Mogushi K, Shimada S, Akiyama Y, Aihara A, et al. CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells. International journal of oncology. 2016;48(2):657-69spa
dc.relation.references21. Kumar V. Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic signalling. 2013;9(2):145-65.spa
dc.relation.references22. de Leve S, Wirsdorfer F, Jendrossek V. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy. Frontiers in immunology. 2019;10:698.spa
dc.relation.references23. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. Journal of translational medicine. 2004;2(1):18.spa
dc.relation.references24. Metcalfe E, Arik D, Oge T, Etiz D, Yalcin OT, Kabukcuoglu S, et al. CD105 (endoglin) expression as a prognostic marker of angiogenesis in squamous cell cervical cancer treated with radical radiotherapy. Journal of cancer research and therapeutics. 2018;14(6):1373-8.spa
dc.relation.references25. Lopez-Novoa JM, Bernabeu C. The physiological role of endoglin in the cardiovascular system. American journal of physiology Heart and circulatory physiology. 2010;299(4):H959-74.spa
dc.relation.references26. Lv FJ, Tuan RS, Cheung KM, Leung VY. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem cells. 2014;32(6):1408-19. Impacto del cultivo de células madre y sus aplicacionesspa
dc.relation.references27. Chosa N, Ishisaki A. Two novel mechanisms for maintenance of stemness in mesenchymal stem cells: SCRG1/BST1 axis and cell-cell adhesion through N-cadherin. The Japanese dental science review. 2018;54(1):37-44.spa
dc.relation.references28. Uder C, Bruckner S, Winkler S, Tautenhahn HM, Christ B. Mammalian MSC from selected species: Features and applications. Cytometry Part A : the journal of the International Society for Analytical Cytology. 2018;93(1):32-49.spa
dc.relation.references29. Serna-Cuéllar E, Santamaría-Solís L. Protocolo de extracción y procesamiento de células madre adultas del tejido adiposo abdominal: coordenadas del cirujano plástico en la investigación traslacional. Cirugía Plástica Ibero-Latinoamericana. 2013;39:s44-s50spa
dc.relation.references30. Brizuela C C, Galleguillos G S, Carrión A F, Cabrera P C, Luz C P, Inostroza S C. Aislación y Caracterización de Células Madre Mesenquimales Provenientes de Pulpa y Folículo Dentario Humano. International Journal of Morphology. 2013;31:739-46.spa
dc.relation.references31. Arbósa. A, Nicolau. F, Quetglas. M, Ramis. JM, Monjo. M, Muncunill. J, et al. Obtención de células madre mesenquimales a partir de cordones umbilicales procedentes de un programa altruista de donación de sangre de cordón. Inmunología. 2013;32(1):1-40.spa
dc.relation.references32. Mizuno M, Katano H, Otabe K, Komori K, Kohno Y, Fujii S, et al. Complete human serum maintains viability and chondrogenic potential of human synovial stem cells: suitable conditions for transplantation. Stem cell research & therapy. 2017;8(1):144.spa
dc.relation.references33. Hornberger K, Yu G, McKenna D, Hubel A. Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie. 2019;46(3):188-96spa
dc.relation.references34. Irdani T, Mazzanti B, Ballerini L, Saccardi R, Torre R. A non-traditional approach to cryopreservation by ultra-rapid cooling for human mesenchymal stem cells. PloS one. 2019;14(7):e0220055.spa
dc.relation.references35. Mizukami A, Swiech K. Mesenchymal Stromal Cells: From Discovery to Manufacturing and Commercialization. Stem cells international. 2018;2018:4083921.spa
dc.relation.references36. Centeno EGZ, Cimarosti H, Bithell A. 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling. Molecular neurodegeneration. 2018;13(1):27.spa
dc.relation.references37. Ho BX, Pek NMQ, Soh BS. Disease Modeling Using 3D Organoids Derived from Human Induced Pluripotent Stem Cells. International journal of molecular sciences. 2018;19(4).spa
dc.relation.references38. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76.spa
dc.relation.references39. Oh KW, Moon C, Kim HY, Oh SI, Park J, Lee JH, et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem cells translational medicine. 2015;4(6):590-7.spa
dc.relation.references40. Kim HY, Kim H, Oh KW, Oh SI, Koh SH, Baik W, et al. Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator- initiated trial and in vivo study. Stem cells. 2014;32(10):2724-31.spa
dc.relation.references41. Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, et al. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. JAMA neurology. 2016;73(3):337-44spa
dc.relation.references42. Staff NP, Madigan NN, Morris J, Jentoft M, Sorenson EJ, Butler G, et al. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Neurology. 2016;87(21):2230-4.spa
dc.relation.references43. Sykova E, Rychmach P, Drahoradova I, Konradova S, Ruzickova K, Vorisek I, et al. Transplantation of Mesenchymal Stromal Cells in Patients With Amyotrophic Lateral Sclerosis: Results of Phase I/IIa Clinical Trial. Cell transplantation. 2017;26(4):647-58.Impacto del cultivo de células madre y sus aplicacionesspa
dc.relation.references44. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Archives of neurology. 2010;67(10):1187-94.spa
dc.relation.references45. Connick P, Kolappan M, Patani R, Scott MA, Crawley C, He XL, et al. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials. 2011;12:62.spa
dc.relation.references46. Llufriu S, Sepulveda M, Blanco Y, Marin P, Moreno B, Berenguer J, et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PloS one. 2014;9(12):e113936.spa
dc.relation.references47. Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem cells and development. 2011;20(8):1297-308.spa
dc.relation.references48. Mendonca MV, Larocca TF, de Freitas Souza BS, Villarreal CF, Silva LF, Matos AC, et al. Safety and neurological assessments after autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury. Stem cell research & therapy. 2014;5(6):126.spa
dc.relation.references49. Oh SK, Choi KH, Yoo JY, Kim DY, Kim SJ, Jeon SR. A Phase III Clinical Trial Showing Limited Efficacy of Autologous Mesenchymal Stem Cell Therapy for Spinal Cord Injury. Neurosurgery. 2016;78(3):436-47; discussion 47.spa
dc.relation.references50. Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem cells. 2014;32(5):1254-66.spa
dc.relation.references51. Pers YM, Rackwitz L, Ferreira R, Pullig O, Delfour C, Barry F, et al. Adipose Mesenchymal Stromal Cell-Based Therapy for Severe Osteoarthritis of the Knee: A Phase I Dose-Escalation Trial. Stem cells translational medicine. 2016;5(7):847-56.spa
dc.relation.references52. Sanchez-Guijo F, Caballero-Velazquez T, Lopez-Villar O, Redondo A, Parody R, Martinez C, et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014;20(10):1580-5.spa
dc.relation.references53. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versushost disease. Transplantation. 2006;81(10):1390-7.spa
dc.relation.references54. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graftversus- host disease in a compassionate use study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011;17(4):534-41.spa
dc.relation.references55. Dhere T, Copland I, Garcia M, Chiang KY, Chinnadurai R, Prasad M, et al. The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn’s disease - a phase 1 trial with three doses. Alimentary pharmacology & therapeutics. 2016;44(5):471-81.spa
dc.relation.references56. Forbes GM, Sturm MJ, Leong RW, Sparrow MP, Segarajasingam D, Cummins AG, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn’s disease refractory to biologic therapy. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2014;12(1):64-71.spa
dc.relation.references57. Soeder Y, Loss M, Johnson CL, Hutchinson JA, Haarer J, Ahrens N, et al. First-in-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation After Liver Transplantation. Stem cells translational medicine. 2015;4(8):899-904spa
dc.relation.references58. Shi M, Zhang Z, Xu R, Lin H, Fu J, Zou Z, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem cells translational medicine. 2012;1(10):725-31.spa
dc.relation.references59. Kharaziha P, Hellstrom PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. European journal of gastroenterology & hepatology. 2009;21(10):1199-205.spa
dc.relation.references60. Reinders ME, de Fijter JW, Roelofs H, Bajema IM, de Vries DK, Schaapherder AF, et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem cells translational medicine. 2013;2(2):107-11.spa
dc.relation.references61. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. Jama. 2012;308(22):2369-79spa
dc.relation.references62. Lee JW, Lee SH, Youn YJ, Ahn MS, Kim JY, Yoo BS, et al. A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. Journal of Korean medical science. 2014;29(1):23-31.spa
dc.relation.references63. Hawsawi YM, Al-Zahrani F, Mavromatis CH, Baghdadi MA, Saggu S, Oyouni AAA. Stem Cell Applications for Treatment of Cancer and Autoimmune Diseases: Its Promises, Obstacles, and Future Perspectives. Technology in cancer research & treatment. 2018;17:1533033818806910spa
dc.relation.references64. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. Bioscience reports. 2015;35(2).spa
dc.relation.references65. Zakrzewski W, Dobrzynski M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. Stem cell research & therapy. 2019;10(1):68.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)spa
dc.subject.lembCultivo de células madre
dc.subject.lembEstudio controlado
dc.subject.lembEmbarazo
dc.subject.proposalCélulas madrespa
dc.subject.proposalCultivo de célulasspa
dc.subject.proposalAislamiento de células madre para cultivospa
dc.type.coarhttp://purl.org/coar/resource_type/c_2f33spa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/bookspa
dc.type.redcolhttps://purl.org/redcol/resource_type/LIBspa
dc.identifier.local616.02774 ed. 23
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dc.rights.coarhttp://purl.org/coar/access_right/c_16ecspa


Ficheros en el ítem

Thumbnail
Nombre:
2_Impacto del Cultivo de Celulas ...
Tamaño:
3.002Mb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

https://creativecommons.org/licenses/by-nc-nd/4.0/
Excepto si se señala otra cosa, la licencia del ítem se describe como https://creativecommons.org/licenses/by-nc-nd/4.0/